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Nutrition plays a fundamental role in supporting the structural and functional
development of the human brain from conception, throughout early infancy and extend-
ing into later life. A growing body of evidence suggests that folate and the metabolically
related B-vitamins are essential for brain health across all age groups, owing to their
speciﬁc roles in C1 metabolism and particularly in the production of S-adenosylmethio-
nine, a universal methyl donor essential for the production of neurotransmitters.
Emerging, though not entirely consistent, evidence suggests that maternal folate status
throughout pregnancy may inﬂuence neurodevelopment and behaviour of the offspring.
Furthermore optimal B-vitamin status is associated with better cognitive health in age-
ing. Of note, a recent clinical trial provided evidence that supplementation with folic
acid and related B-vitamins over a 2-year-period reduced global and regional brain
atrophy, as measured by MRI scan in older adults. In terms of potential mechanisms,
the effects of these B-vitamins on cognitive health may be independent or may
be mediated by nutrient–nutrient and/or relevant gene–nutrient interactions.
Furthermore, a new area of research suggests that the in utero environment inﬂuences
health in later life. Folate, an important cofactor in C1 metabolism, is indirectly
involved in DNA methylation, which in turn is considered to be one of the epigenetic
mechanisms that may underlie fetal programming and brain development. The present
review will explore the evidence that supports a role for folate and the related
B-vitamins in brain health across the lifecycle, and potential mechanisms to explain
such effects.
C1 metabolism: Maternal folate: B-vitamins: Cognitive performance: Cognitive health
Brain development is subject to complex lifelong pro-
cesses of interactions between genetic and environmen-
tal factors. Although many environmental factors
contribute to brain development, nutrition is of par-
ticular importance through the role that nutrients
play in speciﬁc metabolic pathways and structural com-
ponents(1). It is known, for example, that a dietary
deﬁciency during critical periods of development can
result in permanent changes to the brain(2). Of particu-
lar importance are folate and the related B-vitamins
that are involved in C1 metabolism and in the pro-
duction of S-adenosylmethionine (SAM), a universal
methyl donor required for various reactions, including
the production of neurotransmitters(3). B-vitamins are
required for essential brain metabolic pathways and
are fundamental in all aspects of brain development
and maintenance of brain health throughout the
lifecycle(4).
This review will explore the evidence linking maternal
folate status with neurocognitive development in the off-
spring and will consider the associated explanatory
mechanisms. In addition, the roles of B-vitamins and
relevant genetic interactions in relation to cognitive
health in older adults will also be examined.
*Corresponding author: Dr Kristina Pentieva, email k.pentieva@ulster.ac.uk
Abbreviations: IGF2, insulin-like growth factor 2; MTHFR, methylenetetrahydrofolate reductase; RCT, randomised controlled trial; SAM,
S-adenosylmethionine.
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The role of folate and related B-vitamins in C1
metabolism
Folate, a substrate of various enzyme reactions, along
with vitamins B12, B6 and riboﬂavin in their co-factor
forms, are involved in C1 metabolism, which comprises
a network of interrelated biochemical pathways that do-
nate and regenerate C1 units, including methyl groups
(Fig. 1). Within the folate cycle tetrahydrofolate acquires
a carbon unit from serine in a vitamin B6-dependent
reaction, which subsequently forms 5, 10-methylenetetra-
hydrofolate. The latter is involved in the synthesis of thy-
midine, which in turn is incorporated into DNA or it is
converted to 5-methyltetrahydrofolate which participates
in a riboﬂavin (i.e. FAD)-dependent reaction, catalysed
by the enzyme methylenetetrahydrofolate reductase
(MTHFR). 5-Methyltetrahydrofolate then serves as sin-
gle carbon donor, feeding into the C1 pathway by donat-
ing its methyl group to homocysteine to form methionine,
via the vitamin B12-dependent enzyme methionine
synthase. Methionine is a precursor for the synthesis of
SAM, a methyl donor required for the methylation of
DNA, proteins, chromosomes and phospholipids, pro-
duction of myelin and the synthesis and activation of neu-
rotransmitters, including catecholamine and serotonin(5).
Upon donating its methyl group, SAM is converted to
S-adenosylhomocysteine and homocysteine, which can
be further metabolised in the transsulphuration pathway
to form cysteine, a B6-dependent process, or remethylated
back to methionine.
It is important to note that some genetic factors may
affect the function of enzyme activity, leading to
disturbances in B-vitamin absorption, transport and up-
take. Of particular interest is the common 677CT
polymorphism in the gene coding for MTHFR, and
this polymorphism is an important genetic determinant
of plasma homocysteine. Individuals with the homo-
zygous mutant MTHFR 677TT genotype have reduced
MTHFR enzyme activity. Homozygosity for this poly-
morphism alters B-vitamin requirements and has been
linked to a number of degenerative diseases, including
cognitive dysfunction(6).
C1 metabolism, B-vitamins and early brain health
The role of folate in fetal brain development
Optimal folate status is essential throughout pregnancy
for placental and fetal growth and development.
During pregnancy there is a decline in maternal folate
concentrations to approximately 50 % of non-pregnant
concentrations(7). This is partly owing to the increased
folate requirements for rapid cell proliferation and tissue
growth of the uterus and placenta, growth of the fetus
and for the expansion of maternal blood volume(8).
Irrefutable evidence has shown that supplementation
with folic acid protects against both ﬁrst occurrence(9)
and recurrence(10) of neural tube defects, leading to
government recommendations, which are in place world-
wide, advising all women planning a pregnancy to con-
sume 400 μg folic acid/d from preconception until the
end of the ﬁrst trimester of pregnancy(11,12). This protec-
tive effect of folic acid supplementation relates to the
Fig. 1. (colour online) C1 metabolism. PLP, pyridoxal 5
′ phosphate; MTHFR, methylenetetrahydrofolate
reductase; DMG, dimethylglycine; dTMP, deoxythymidine monophosphate; dUMP, deoxyuridine
monophosphate. (Adapted from Clarke et al.(85))
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early stages of pregnancy when the closure of the neural
tube occurs (about 21–28 d post-conception); however,
little is known as to whether continuing folic acid usage
throughout pregnancy confers any long-term beneﬁcial
effects to the offspring.
There is a growing body of evidence from observa-
tional and experimental studies, suggesting that nutrition
in uteromay affect later cognitive development in the off-
spring. As the fetal brain develops rapidly, poor maternal
intake of key nutrients during pregnancy can inﬂuence
the development of the structure and components of
the brain. Folate and the metabolically related
B-vitamins are fundamental throughout brain develop-
ment via their participation in transcription, nucleotide
synthesis, neurotransmitter production and methylation
processes, including DNA methylation(13).
Evidence linking maternal folate status with offspring
cognitive performance
In recent years, the association between maternal folate
and/or related B-vitamin status with later cognitive per-
formance of the offspring has become a topic of interest.
To date most of the literature in this area is derived from
observational (Table 1) and animal studies. Given the
recognised protection of folic acid in the prevention of
neural tube defect during early fetal development, the
majority of these studies reported peri-conceptional use
of folic acid by women and are focused in the early stages
pregnancy. Only a few studies have investigated maternal
folate status in the second and third trimesters of preg-
nancy, i.e. after the recommended period, in relation to
later cognitive performance of the child, and no available
human evidence has addressed this question in a rando-
mised trial in pregnancy.
A number of human studies have shown positive asso-
ciations between self-reported folic acid supplement use
during the ﬁrst trimester of pregnancy and cognitive per-
formance of the child(15,17–19). Julvez et al.(15) demon-
strated that folic acid use in pregnancy was associated
with improved neurodevelopment, verbal performance
and motor development in children aged 4 years.
Similarly, a large longitudinal study (n 1210) examined
the association between maternal intake of methyl
donor nutrients, including folate and vitamin B12, during
the ﬁrst trimester of pregnancy in relation to the cogni-
tive performance of the offspring. The authors estimated
that each 600 μg/d increment in total folate intake (from
food and supplements combined) was associated with a
1·6 point higher score in cognitive performance in the
child, assessed at age 3 years(19). Likewise, another
observational study indicated signiﬁcantly higher verbal
comprehension, vocabulary development and communi-
cation skills in Greek children born to mothers taking
high dose folic acid (5 mg/d) in pregnancy, compared
with those whose mothers did not take supplements(18).
Most notably, evidence from a large prospective study
(n 38 954) in the US-linked maternal folic acid sup-
plement use from 4 to 8 weeks after conception with a
reduced risk of severe language delay evaluated by self-
reported parental questionnaires assessing the grammar
of the child, at age 3 years(17).
During the growth spurt in pregnancy (about 24–42
gestational weeks), the developing brain, owing to the se-
quence of developmental stages, including neuronal pro-
liferation and myelination, is particularly vulnerable to
adequate nutrition(20). Throughout the late fetal and
early postnatal periods areas such as the hippocampus,
auditory and visual cortices and the striatum undergo
rapid growth by morphogenesis and synaptogenesis
which makes them functionally active(21). All nutrients
are important for brain development, but it is proposed
that certain nutrients, including folate, have greater ef-
fects during the late fetal development. Only a few stu-
dies, however, have investigated the impact of maternal
folate status in the later stages of pregnancy on the child’s
neurodevelopment. Nearly 40 years ago, Gross et al.(14)
reported that children born to mothers with diagnosed
megaloblastic anaemia during the third trimester of preg-
nancy had abnormal neurodevelopment and lower intel-
lectual abilities compared with infants born to mothers
with optimal folate status. Several decades later a study
investigating the impact of maternal blood folate, B12
and homocysteine concentrations, at 30 gestational
Table 1. Observational studies investigating the association between maternal folate status with cognitive performance of the offspring
Reference
Sample
size Maternal folate status Age of child
Cognitive
assessment Main outcome
Gross et al.(14) 14 Diagnosed megaloblastic
anaemia, third trimester
6 weeks–4
years
DDST Maternal folate deﬁciency associated with
abnormal neurodevelopment
Julvez et al.(15) 420 Self-reported, ﬁrst trimester 4 years MSCA FA associated with improved cognition
Venna et al.(16) 536 Blood samples at 30th GW 9–10 years KABCTM-II FA in late pregnancy associated with better
cognitive performance
Roth et al.(17) 39 954 Self-reported, ﬁrst trimester 3 years Language
Grammar Scale
FA associated with reduced language delay
Chatzi et al.(18) 553 Self-reported, ﬁrst trimester 18 months Bayley-III FA associated with vocabulary, communication
and verbal skills
Villamor et al.(19) 1210 Self-reported, ﬁrst trimester 3 years PPVT-III &
WRAVMA
FA associated with increased cognitive
performance
FA, folic acid; GW, gestational week; PPVT, Peabody Picture Vocabulary Test; WRAVMA, Wide Range Assessment of Visual Motor Abilities; DDST, Denver
Development Screening Test; MSCA, McCarthy Scales of Children’s Abilities; KABCTM -II, Kaufman Assessment Battery, 2nd edition; Bayley-III, Bayley Scales of
Infant and Toddler Development, 3rd edition.
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weeks, in relation to cognitive performance of 9–10-year-
old children (n 536), showed that higher maternal folate
status during late pregnancy predicted better cognitive
performance in children(16). No association was observed
for maternal B12 or homocysteine status on the overall
cognitive ability of the children(16).
To date no randomised controlled trial (RCT) has
investigated the effect of maternal folate status during
the later stages of pregnancy and subsequent cognitive
performance of the offspring. A pilot study (n 39),
conducted by our group, examined the effect of folic
acid supplementation in the second and third trimester
of pregnancy and subsequent cognitive performance of
the child. The novel results showed that children (aged
3 years) born to mothers supplemented with folic
acid, scored signiﬁcantly higher in the cognitive domain
of the Bayley’s development assessment(22). These highly
promising results from this RCT now need to be
conﬁrmed on a larger scale.
Mechanistic studies in animal models also provide evi-
dence that prenatal folate deﬁciency may be causally re-
lated to adverse structural changes in the brain(23,24).
Craciunescu et al.(24) reported that the offspring of rats
fed a folic acid deﬁcient diet during days 11 and 17 of
gestation (i.e. corresponding to mid- and late stages of
human pregnancy), had a reduction in progenitor cells
in the fetal neocortex (an area responsible for complex
behaviours, including cognition) suggesting that the de-
veloping fetal brain is vulnerable to maternal folate deﬁc-
iency, which may adversely affect cognitive performance
in the later life(24). Similarly, another study showed that
gestational B-vitamin deﬁciency resulted in an accumu-
lation of homocysteine with ‘concomitant apoptosis’ in
selective brain areas, the cerebellum, striatum and hippo-
campus, which altered motor function and learning and
memory abilities in rats(25).
Evidence regarding the impact of maternal folate status
on the offspring neurodevelopment is further strength-
ened by genetic studies. The common 677CT poly-
morphism in the gene coding for the folate metabolising
enzyme MTHFR is an important genetic determinant
of plasma homocysteine and individuals homozygous
for the polymorphism (MTHFR 677TT genotype), are
prone to low folate status and elevated plasma homocys-
teine concentrations. Recent studies from Mexico, where
the frequency of theMTHFR 677TT genotype is reported
to be the highest in the world(26), showed that the ma-
ternal MTHFR 677TT genotype is a predictor of poor
child neurodevelopment(27) especially in combination
with low maternal folate intake (<400 μg/d) during the
ﬁrst trimester of pregnancy(28). However, research in this
area is limited and further studies are required to investi-
gate whether children born to mothers genetically suscep-
tible to impaired folate status are more at risk of impaired
neurodevelopment.
Not all studies support the association between ma-
ternal folate status and the neurodevelopment of the
child. A Hungarian RCT investigating pregnant
women consuming a multi-vitamin containing folic acid
(0·8 mg/d) before conception until the second month of
pregnancy did not ﬁnd any evidence of improved ‘mental
development’ of children aged 6 years(29). The present
study, however, was primarily designed to investigate
the effect of folic acid on neural tube defects during the
very early stages of pregnancy. Likewise a longitudinal
study found no evidence of an association between ma-
ternal blood folate status (low ≤11 nmol v. normal >11
nmol/l) in the later stages of pregnancy (19, 26 and 37
gestational weeks) and cognitive performance of children
aged 5 years(30). Possible reasons to explain these incon-
sistencies may include the inﬂuence of socio-economic
status, a well-known confounder for cognitive develop-
ment and which could potentially confound any effect
of folic acid(30). Furthermore, the studies by Dobo &
Czeiel(29) and Tamura et al.(30) used a multi-vitamin ap-
proach, rather than folic acid alone; an approach, which
again could impact the ﬁndings.
Overall, the observational and animal evidence appears
to be supportive for a role of maternal folate status in
later cognitive performance of the child. Aside from cog-
nitive health, there are also studies linking low maternal
folate status with higher offspring behavioural(31), inat-
tention and hyperactivity problems(32) and emotional
problems(33), which warrant further investigation. It is im-
portant to note however that much of the observational
evidence is based on self-reported folic acid usage, usually
during the early fetal development stages(15,17–19), with
only a few studies exploring the effect of supplementation
during later stages of pregnancy(14,16) and none doing so
using a RCT. Considering that there is rapid structural
and synaptic development in key areas of the brain, in-
cluding the hippocampus, during the growth spurt in
pregnancy, further studies are required to more fully in-
vestigate the potential effect of folate throughout preg-
nancy and to determine if the effect is speciﬁc to certain
stages of pregnancy or perhaps the effect is mediated
throughout all trimesters of pregnancy.
Other evidence supporting folate status in relation to
brain health in the young
The effect of dietary and blood folate status on cognitive
performance has also been investigated in young children
and adolescents. A recent study by Strand et al.(34)
reported that low plasma folate and vitaminB12 concentra-
tions were associated with poorer cognitive performance,
measured in children aged 12–18 months. Furthermore,
an investigation of Swedish adolescents (age 15 years)
showed that higher dietary folate intakes was positively
associated with academic achievements(35). Nguyen
et al.(36) also reported that higher serum folate measured
in children aged 6–16 years was associated with higher per-
formance in reading and also in block design in partici-
pants from the National Health and Nutrition
Examination Survey III cohort in the USA.
C1 metabolism, B-vitamins and brain health in ageing
Cognitive dysfunction and dementia
Cognitive dysfunction is a common problem among the
ageing population and ranges in severity from mild
C. Mcgarel et al.4
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cognitive impairment to more progressive types of de-
mentia; the latter referring to a state in which the disease
is sufﬁcient to impair normal way of living(37,38).
Although some degree of cognitive decline is considered
a normal and an unpreventable aspect of ageing, the de-
velopment of dementia and Alzheimer’s disease is at-
tributable to diseases of the brain, resulting in changes
to the brain structure sufﬁcient to interfere with normal
life activities. Globally an estimated 35·6 million people
suffer from dementia, affecting 7 % of individuals aged
over 65 years and 30 % of those over 80 years(39).
Given the increase in life expectancy, these ﬁgures are
expected to double worldwide by 2025(39) and represents
a major public health challenge for future generations.
As brain changes start to progress long before the di-
agnosis of dementia is overt, it is important to ﬁnd
early biomarkers that would enable timely interventions
to delay the onset or slow the progression of the dis-
ease(40). Well-established non-modiﬁable risk factors in-
clude increasing age, family history and genetic factors.
However, evidence has now amassed from long-term epi-
demiological studies linking potentially modiﬁable life-
style factors, including smoking status, physical
inactivity and nutritional factors with cognitive dysfunc-
tion. Emerging evidence suggests that suboptimal status
of folate and the metabolically related B-vitamins and/
or elevated homocysteine concentrations, owing to their
essential roles in C1 metabolism may be linked with cog-
nitive dysfunction and dementia.
Evidence linking B-vitamins with brain health in ageing
The majority of epidemiological studies generally sup-
port an association between suboptimal status of folate,
the metabolically related B-vitamins or elevated con-
centrations of the metabolite homocysteine with cognitive
dysfunction in older adults. Indeed, a review by Smith (41)
some years ago reported that 90 out of 100 published
cross-sectional and prospective studies showed a link be-
tween elevated homocysteine and/or low B-vitamins con-
centrations with cognitive dysfunction. Most of these
studies have focused on elevated plasma homocysteine
concentrations(42–46), and/or a combination of suboptimal
status of folate and vitamin B12
(47–54) and to a much lesser
extent on vitamin B6
( 55,56). To the authors’ knowledge, no
published study thus far has focused on riboﬂavin alone as
a potential contributor to cognitive health. Notably, there
are a number of limitations associated with these studies;
typically, only one cognitive assessment tool was used,
rather than a battery of tests providing information for
multiple cognitive domains; depression and anxiety
(known confounders) are not measured and there is a
lack of data on vitamin supplement usage, all of which
can limit the reliability of reported results.
It is also important to take into consideration recent
concerns regarding mandatory folic acid fortiﬁcation and
the potential ‘masking’ effect of vitamin B12 deﬁciency
among older adults. In B12 deﬁciency, the activity of meth-
ionine synthase is reduced; therefore 5, methyltetrahydro-
folate cannot be converted to tetrahydrofolate (the active
form of folate) and becomes trapped in an unusable
form. Evidence from the National Health and Nutrition
Examination Survey reported that although higher folate
was generally associated with better cognitive health, a
combination of high plasma folate (>59 nmol/l) with low
plasma B12 (<148 pmol) and elevated methylmalonic
acid (a B12-speciﬁc functional biomarker), was actually
associated with poorer cognitive performance compared
with individuals with normal concentrations of these bio-
markers(57). Furthermore, Moore et al.(58) showed partici-
pants with high red cell folate and low serumB12were three
times more likely to have impaired cognitive performance.
In contrast, however, analysis from the Hordaland Health
study failed to conﬁrm this association in their analysis(59).
The disagreement between studies is possibly linked to the
relatively small sample of participants with the combi-
nation of high folate and lowB12 status available for analy-
sis in these studies. In addition, high and low status of
folate and B12 is deﬁned differently among various pub-
lished studies.
Following the positive associations from epidemiologi-
cal evidence a number of RCT have investigated the po-
tential beneﬁts of B-vitamin supplementation on
cognitive health (Table 2). Many of these trials however
were of insufﬁcient power and duration to detect an ef-
fect or included participants with existing optimal
B-vitamin status or with advanced dementia, where a
beneﬁcial effect is not likely(60,62,67–70).
Notably, two similarly designed homocysteine-lowering
trials have yielded conﬂicting results. The Folic Acid and
Carotid Intimamedia Thickness (FACIT) trial found that
supplementation with 800 μg folic acid/d over 3 years in
healthy adults’ (n 818) improved global cognitive func-
tion, in particular memory, information processing
speed and sensorimotor speed(61). In contrast, a 2-year
trial also conducted in healthy individuals (n 276) supple-
mented with a combination of folate (1000 μg/d), B12
(500 μg/d) and B6 (10 mg/d) or placebo, reported no sign-
iﬁcant effect on cognitive performance, across the eight
cognitive assessments used(60). Although these studies
were of similar design, sufﬁciently powered, had compar-
able baseline cognitive scores and used similar exclusion
criteria, it is important to note the difference in the base-
line folate status of participants between these two trials.
The baseline folate (12 nmol/l) was lower in the FACIT
trial compared with the McMahon study (baseline folate
22·6 nmol/l), which may suggest that any beneﬁts of
folic acid on cognitive health in ageing may arise from
correcting suboptimal folate status, whereas supplement-
ing with additional folic acid to those with optimal status
may not provide any further beneﬁt to cognitive function.
More recently, a signiﬁcant improvement in overall cogni-
tive performance was found following a 2-year inter-
vention with B-vitamins in participants with elevated
psychological distress(64). The majority of the reported in-
tervention trials used questionnaire-based assessments of
cognitive performance; very few clinical trials have in-
vestigated the effect of B-vitamins on cognitive dysfunc-
tion using direct methods, such as brain imaging
techniques, which may provide a more robust measure
of long-term brain changes, including the impact of
nutritional interventions.
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The strongest evidence to date originates from the
VITACOG trial in Oxford, in which patients with mild
cognitive impairment (without dementia) were supple-
mented with folic acid (800 μg/d), B12 (500 μg/d) and
B6 (20 mg/d) or placebo over a 2-year period. The results
reported that supplementation with B-vitamins slowed
the rate of cognitive decline, assessed by questionnaire-
based cognitive tests(63). Of greater importance is the
fact that the same study also found that B-vitamin
treatment reduced brain atrophy, as measured by MRI
scans, by approximately 30 %(65). The effect was greatest
in participants with the highest baseline homocysteine
concentrations (>13 μmol/l), among whom an overall re-
duction of brain atrophy rate of 53 % was reported, while
no effect was found in those in the bottom quartile (≤9·5
μmol/l)(65). Moreover, when a subsample of VITACOG
cohort were further analysed, the investigators reported
that B-vitamin treatment reduced the cerebral atrophy,
by as much as 7-fold, speciﬁcally in grey matter areas
of the brain vulnerable to Alzheimer’s disease, including
bilateral hippocampus and cerebellum(66). Finally, when
participants were analysed by quartiles for brain shrink-
age, it was reported that participants with the highest rate
of brain shrinkage displayed the most cognitive de-
cline(71). Importantly, folate, vitamin B12 and vitamin
B6 are all required to lower concentrations of homocys-
teine and perhaps it is the combination of B-vitamins,
and not a monotherapy B-vitamin approach, which is
required to optimise C1 metabolism. This research has
paved the way for future RCT in this area; more research
is however warranted in both healthy and cognitively
impaired groups to investigate the proposed effect
further.
In summary, results from large observational studies
conducted in healthy and cognitively impaired cohorts
provide strong evidence of a possible relationship between
suboptimal B-vitamin status, elevated homocysteine
(independently or as a marker of B-vitamin status) and
cognitive dysfunction. At present the most promising evi-
dence supporting a cause and effect relationship comes
from the VITACOG trial(63,65,66,71). These ﬁndings now
require replication in other population groups to
conﬁrm the role played by B-vitamins in cognitive health.
If cognitive dysfunction can in fact be slowed or pre-
vented by B-vitamins, in healthy older people, then this
could offer a cost-effective preventative public health
strategy in ageing populations.
Potential mechanisms linking B-vitamins with brain
health
Potential mechanism explaining the role of B-vitamins in
early brain development
B-vitamins appear to have direct roles on brain develop-
ment and maintenance, through their involvement in C1
metabolism. A new emerging area of research concerns
the role of epigenetics, which is broadly deﬁned as the
‘heritable changes in gene function that cannot be
explained by changes in the DNA sequence’(72).
Epigenetic alternations in utero may have the potential
to programme diseases in adulthood. Studies have re-
cently begun to investigate whether epigenetic modi-
ﬁcation, through nutritional interventions, can inﬂuence
an individual’s health in later life. DNA methylation
is the most widely studied epigenetic mechanism and
occurs through C1 metabolism, which is dependent on
folate and several cofactors, including the related
B-vitamins.
A number of animal studies have addressed the issue
of maternal folate status and subsequent epigenetic effect
on the offspring. Waterland & Jirlte(73) demonstrated
that in pregnant agouti mice a high methyl diet, resulted
in offspring with mottled brown coats, which were less
Table 2. Summary of randomised trials assessing the effect of B-vitamin treatment on cognitive function in older adults
Reference
Sample
size (n)
Age
(years) Population Duration Treatment Main outcome
Questionnaire-based assessment
McMahon et al.(60) 276 ≥65 Healthy individuals hcy
≥13 μmol/l
2 years 1000 μg FA, 500 μg
B12, 10 mg B6
No signiﬁcant effects on cognition
Durga et al.(61) 818 50–70 Healthy individuals hcy
≥13 μmol/l
3 years 800 μg FA Improved domains of cognitive
function
Aisen et al.(62) 304 ≥50 Mild to moderate AD 18 months 5 mg FA, 1 mg B12,
25 mg B6
No signiﬁcant effects on cognition
deJager et al.(63) 233 ≥70 MCI 2 years 800 μg FA, 500 μg
B12, 20 mg B6
B-vitamin treatment slowed cognitive
decline
Walker et al.(64) 900 60–74 Elevated psychological
distress
2 years 400 μg FA, 100 μg
B12
B-vitamin treatment improved
cognitive function
Brain-imaging assessment
Smith et al.(65) 168 ≥70 MCI 2 years 800 μg FA, 500 μg
B12, 20 mg B6
B-vitamin treatment slowed the rate of
brain atrophy
Douaud et al.(66) 156 ≥70 MCI 2 years 800 μg FA, 500 μg
B12, 20 mg B6
B-vitamin treatment reduced grey
matter atrophy is regions associated
with AD
FA, folic acid; hcy, homocysteine; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
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obesogenic and less prone to diseases. Interestingly,
methyl donor supplementation of agouti pregnant dams
appeared to not only affect the fetus, but also the sub-
sequent generation, suggesting that the maternal diet
may inﬂuence several generations(74). Recently, Cho
et al.(75) also provided evidence of the epigenetic effects
of folate supplementation in pregnancy and showed
that a high folate diet throughout pregnancy and wean-
ing resulted in dams less exposed to an obseogenic
phenotype. Collectively, these studies show that restric-
tion in folate can inﬂuence DNA methylation in the off-
spring and in turn inﬂuence gene expression and disease
related phenotypes.
The results from human studies, although limited, are
also generally supportive of the effect of folate on epi-
genetic processes. Evidence from the Dutch Hunger
Winter study has shown that malnutrition (in this case
because of extreme famine) during pregnancy may
induce permanent epigenetic changes in IGF2(76,77).
Recent studies suggest that IGF2 epigenetic changes in
utero are associated with long-term metabolic health
risk in human subjects(77). The results from Steegers-
Theunissen et al.(78) showed that reported maternal
folic acid supplement usage was associated with an
increased methylation (4·5 %) of IGF2 differentially
methylated region of the offspring, 17 months after deliv-
ery. Moreover, maternal SAM concentrations were re-
lated to the offspring IGF2 differentially methylated
region’s methylation levels, indicating that the maternal
environment had a greater inﬂuence on the methylation
of IGF2 in the offspring(78). In further support, results
from an observational study (n 913) investigating the ef-
fect of folic acid use after the recommended 12 gesta-
tional weeks, reported that supplement use was
associated with signiﬁcant, albeit small, elevation in
IGF2 methylation and reduced methylation in paternally
expressed 3 (PEG3) and LINE-1(79). No effect was
observed before 12 weeks gestation; perhaps suggesting
an epigenetic effect of folate occurred during the later
stages of pregnancy. Considering that IGF2 is involved
in placental and fetal development and PEG3 is a gene
highly expressed in the brain and also involved in the de-
velopment of the fetal hypothalamus(80,81), alterations in
the methylation of these genes may subsequently exert
inﬂuence on their expression, which in turn might have
an impact on the offspring’s brain development.
However, further studies are required to expand on the
current knowledge of nutrition and disease prevention
through epigenetic mechanisms.
Potential mechanism explaining the role of B-vitamins
with brain health in ageing
Mechanisms linking B-vitamins and cognitive health in
ageing are speculative and several hypotheses have been
suggested. Folate and vitamin B12 are required for the pro-
duction of SAM, which in turn is required for various
methylation reactions and adequate production of neuro-
transmitters. Deﬁciencies in these vitaminsmay lead to dis-
turbances in important methylation reactions, which may
affect pathways associated with cognitive health. It is
also proposed that deﬁciencies in folate, vitamins B12 and
B6 can disrupt the remethylation of homocysteine to meth-
ionine, resulting in hyperhomocysteinemia. Studies have
linked elevated plasma homocysteine concentrations with
atrophy of the hippocampus; an area of the brain required
for memory consolidation(82). It is therefore suggested that
high homocysteine concentrations may have direct neuro-
toxic effects, resulting in apoptosis and possibly impairing
pathways associated with cognition(64,83). In addition, op-
timal B6 status plays an important role in brain health
through its essential role in transamination and decarbox-
ylation reactions required for the metabolism of several
neurotransmitters, including serotonin, γ-aminobutyric
acid, dopamine, noradrenaline and histamine(84).
Conclusion
Given the importance of C1 metabolism in a wide array of
processes, including the production of neurotransmitters
and DNA methylation, it is not surprising that distur-
bances in this cycle may have profound effects on both
the developing and ageing brain. Mechanistically it is
clear that folate and the related B-vitamins are critical for
brain function throughout the lifecycle. Some important
questions, however, still need to be considered. The poten-
tial role between maternal folate status during pregnancy
and later neurodevelopment of the offspring needs to be
explored through well-designed RCT. A clearer under-
standing of the role of folate in early brain health will
help to inform future policies in relation to folic acid recom-
mendations in pregnancy. Compelling evidence from epi-
demiological studies and RCT show that there is a strong
association between suboptimal B-vitamin status and/or
elevated homocysteine with an increased risk of cognitive
dysfunction in older adults. Further research from well-
conducted RCT which includes brain-imaging techniques
is warranted to shed light on some fundamental questions.
In conclusion, current evidence suggests that folate and the
metabolically related B-vitamins may be important contri-
butors to brain health across the lifecycle. Improving
knowledge of potential epigenetic mechanisms during
pregnancy and postnatal life will help provide the import-
ant mechanistic links between B-vitamins and brain health.
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